Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 6/20 | 0.95 |
| ▸ | CD44 | P16070 | 2/20 | 0.95 |
| ▸ | MAOB | P27338 | 1/20 | 0.95 |
| ▸ | HTR2C | P28335 | 1/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.52 |
| ▸ | PRCP | P42785 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL19085 | 0.97 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28236302 | 0.97 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL29360217 | 0.97 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL11213530 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL6635293 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL4243903 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL5411332 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL20524019 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL987515 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL2082936 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115702146-A | 5- ((1, 2,3, 4-tetrahydroisoquinolin-7-yl) amino) pyridin-2 (1H) -one derivatives and uses thereof | 苏州恩华生物医药科技有限公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-1436191-B | Antitumor ecteinascidin derivatives | PHARMA MAR SA | 2011-09-14 | — | — | CN | disclosed |
| US-8012975-B2 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | PHARMA MAR, S.A. (ES) | 2011-09-06 | — | — | US | disclosed |
| US-7919493-B2 | A compound having a fused ecteinascidin five ring system with a 1,4 bridge; anticarcinogenic agent | PHARMA MAR, S.A. (ES) | 2011-04-05 | — | — | US | disclosed |
| US-7524956-B2 | Hemisynthetic method and new compounds | PHARMA MAR, S.A. (ES) | 2009-04-28 | — | — | US | disclosed |
| CN-100475822-C | Synthesis method for producing ecteinascidin compound | PHARMA MAR SA (ES) | 2009-04-08 | — | — | CN | disclosed |
| US-7420051-B2 | Antitumor agents; microbiocides; antibiotics; forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18-protected hydroxyl, di-6,8-en-5-one fused ring compound. After formation of the 1,4 brige, C-18 protection is removed before spiroamine introduction | PHARMA MAR, S.A. (ES) | 2008-09-02 | — | — | US | disclosed |
| US-7410969-B2 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2008-08-12 | — | — | US | disclosed |
| US-20080146580-A1 | Anititumoral Ecteinascidin Derivatives | PHARMAMAR (ES) | 2008-06-19 | — | — | US | disclosed |
| US-20080051407-A1 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | PHARMA MAR, S.A., A MADRID SPAIN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| CN-1436193-A | Antitumoral ecteinascidin derivs | PHARMA MAR SA (ES) | 2003-08-13 | — | — | CN | disclosed |
| EP-1289999-A1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR, S.A. (ES) | 2003-03-12 | — | — | EP | disclosed |
| EP-1287004-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF AN ECTEINASCIDIN COMPOUND | PHARMA MAR, S.A. (ES) | 2003-03-05 | — | — | EP | disclosed |
| EP-1280809-A1 | ANTITUMORAL ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2003-02-05 | — | — | EP | disclosed |
| CN-1360588-A | Hemisynthetic method and intermediate thereof | PHARMA MAR SA (ES) | 2002-07-24 | — | — | CN | disclosed |
| EP-1185536-A2 | HEMISYNTHETIC METHOD AND INTERMEDIATES THEREOF | PHARMA MAR, S.A. (ES) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001087894-A1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR, S.A. (ES) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001087895-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF AN ECTEINASCHIDIN COMPOUND | PHARMA MAR, S.A. (ES) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001077115-A1 | ANTITUMORAL ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2001-10-18 | — | — | WO | disclosed |
| WO-2000069862-A2 | HEMISYNTHETIC METHOD AND INTERMEDIATES THEREOF | PHARMA MAR, S.A. (ES) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051407-A1 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | FN1, RCN1, ERCC4 | PNMT 1089/4885CD44 890/4885MAOB 790/4885 |
| US-20080146580-A1 | Anititumoral Ecteinascidin Derivatives | AREG, CD68, ASGR1 | PNMT 587/4885CD44 384/4885MAOB 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.